Mizuho Securities analyst Irina Koffler provided the following quick thought on Valeant Pharmaceuticals (NYSE: VRX) slides and call:· ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Short Sales Trader Talk

Valeant Pharmaceuticals' (VRX) Buy Rating Affirmed at TD SecuritiesOctober 26, 2015 3:33 PM Valeant Pharma (VRX) Halts the Bloodletting Following Conference CallOctober 26, 2015 1:03 PM Valeant (VRX) Answered Its Questions Well, But Other Questions Remain - Deutsche Bank October 26, 2015 11:15 AM Valeant (VRX) CC Seen as Step Forward at BMO Capital But More Needed to Rebuild Investor ConfidenceOctober 26, 2015 10:35 AM UPDATE: Valeant Pharma (VRX) Sees Dramatic Red-to-Green Reversal Then Collapses AgainOctober 26, 2015 9:40 AM Valeant Pharma (VRX) CEO Pearson, Outside Director Ingram Issue Commentary on PhilidorOctober 26, 2015 9:11 AM Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant PharmaceuticalsOctober 26, 2015 9:00 AM Valeant Pharma (VRX) says ad hoc committee will review issues brought up in today's WSJOctober 26, 2015 8:43 AM Valeant Pharma (VRX) Regains Some Early Losses as Conference Call StartsOctober 26, 2015 8:09 AM Dow, S&P 500 end down slightly as Apple, energy weighOctober 26, 2015 7:36 AM Valeant Pharma (VRX) Files Presentation on Philidor; Says No Evidence of Illegal Activity To-DateOctober 26, 2015 7:28 AM Valeant Pharma (VRX) Releases Slides Ahead of Investor Conference CallOctober 26, 2015 7:28 AM WSJ Highlights More 'Smoke' at Valeant Pharma (VRX) Ahead of Conference CallOctober 26, 2015 6:39 AM Valeant Pharma (VRX) Says Philidor Accounting is AppropriateOctober 26, 2015 6:16 AM Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review PhilidorOctober 26, 2015 6:15 AM